---
title: Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38828955/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240603181443&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with CAH, the use of crinecerfont resulted
  in a greater decrease from baseline in the mean daily glucocorticoid dose, including
  a reduction to the physiologic range, than placebo following evaluation of adrenal
  androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov number, ...